HUE047335T2 - Anti-connexin 43 vegyületek, krónikus sebek kezelésére - Google Patents
Anti-connexin 43 vegyületek, krónikus sebek kezeléséreInfo
- Publication number
- HUE047335T2 HUE047335T2 HUE06795121A HUE06795121A HUE047335T2 HU E047335 T2 HUE047335 T2 HU E047335T2 HU E06795121 A HUE06795121 A HU E06795121A HU E06795121 A HUE06795121 A HU E06795121A HU E047335 T2 HUE047335 T2 HU E047335T2
- Authority
- HU
- Hungary
- Prior art keywords
- connexin
- compounds
- treating chronic
- chronic wounds
- wounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65007505P | 2005-02-03 | 2005-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE047335T2 true HUE047335T2 (hu) | 2020-04-28 |
Family
ID=37532679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE06795121A HUE047335T2 (hu) | 2005-02-03 | 2006-02-03 | Anti-connexin 43 vegyületek, krónikus sebek kezelésére |
Country Status (12)
Country | Link |
---|---|
US (2) | US9248141B2 (hu) |
EP (5) | EP1959981B1 (hu) |
JP (6) | JP5964538B2 (hu) |
KR (4) | KR101840445B1 (hu) |
CN (2) | CN108324923A (hu) |
AU (2) | AU2006257283A1 (hu) |
CA (1) | CA2596412A1 (hu) |
DK (1) | DK1959981T3 (hu) |
ES (1) | ES2766549T3 (hu) |
HK (1) | HK1258903A1 (hu) |
HU (1) | HUE047335T2 (hu) |
WO (1) | WO2006134494A2 (hu) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408381B2 (en) | 2004-12-21 | 2016-08-09 | Musc Foundation For Research Development | Alpha Connexin c-Terminal (ACT) peptides for use in transplant |
AU2005319155B2 (en) | 2004-12-21 | 2013-01-31 | Musc Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
WO2006134494A2 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and therapeutic uses thereof |
KR20100027091A (ko) * | 2006-11-15 | 2010-03-10 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
ES2527131T3 (es) | 2006-12-11 | 2015-01-20 | Coda Therapeutics, Inc. | Polinucleótidos anticonexina como composiciones para la curación alterada de heridas |
AU2014204482B2 (en) * | 2006-12-11 | 2016-07-07 | Coda Therapeutics, Inc. | Anticonnexin polynucleotides as impaired wound healing compositions |
JP5552048B2 (ja) * | 2007-06-21 | 2014-07-16 | ムスク ファンデーション フォー リサーチ ディベロップメント | 加齢性黄斑変性を治療するためのアルファコネキシンc末端(act)ペプチド |
WO2009029991A1 (en) | 2007-09-07 | 2009-03-12 | Meat & Livestock Australia Limited | Agents with angiogenic and wound healing activity |
CN101970663A (zh) * | 2007-12-11 | 2011-02-09 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
CN102105492A (zh) * | 2007-12-11 | 2011-06-22 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
CA2710382A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of orthopedic conditions |
CA2710386A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Improved medical devices |
US8975237B2 (en) | 2007-12-21 | 2015-03-10 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
JP2011507855A (ja) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 外科的癒着の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた抗コネキシンペプチドの使用 |
WO2009085269A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions |
WO2009085275A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
CA2710227A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of surgical adhesions |
CA2722671A1 (en) | 2008-04-30 | 2009-11-05 | Amy Mcnulty | Use of nucleic acids with reduced pressure therapy |
WO2009148552A2 (en) * | 2008-06-02 | 2009-12-10 | Kansas State University Research Foundation | Methods and compositions for treating disease |
EP2307546A1 (en) * | 2008-06-04 | 2011-04-13 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
ITCH20080021A1 (it) * | 2008-09-25 | 2010-03-26 | Saverio Alberti | Usi in diagnosi e terapia dei tumori di un rna di fusione tra ciclina d1 e trop2 |
WO2013073968A2 (en) * | 2011-09-12 | 2013-05-23 | Industrial Research Limited | Agents for modulation of cell signalling |
AU2013225716B2 (en) | 2012-03-01 | 2017-10-12 | Xequel Bio, Inc. | Topical gels containing alpha connexin C-terminal (ACT) peptides |
JP2015515282A (ja) * | 2012-04-25 | 2015-05-28 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 創傷治癒および組織修復のための組成物および方法 |
CN104271560B (zh) | 2012-05-08 | 2017-05-24 | 石原产业株式会社 | 取代苯甲酸化合物的制造方法 |
US9879058B2 (en) | 2012-05-30 | 2018-01-30 | Universidad Andres Bello | Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders |
US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
CN106659909B (zh) | 2013-08-21 | 2022-01-11 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
WO2015191795A1 (en) * | 2014-06-12 | 2015-12-17 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
EP3183346A4 (en) | 2014-08-22 | 2018-10-24 | Auckland Uniservices Limited | Channel modulators |
HK1243457A1 (zh) * | 2014-08-22 | 2018-07-13 | Auckland Uniservices Ltd | 通道調節劑 |
AU2015317330B2 (en) | 2014-09-19 | 2021-01-14 | Memorial Sloan-Kettering Cancer Center | Methods for treating brain metastasis |
RU2018102640A (ru) | 2015-07-15 | 2019-08-15 | Теранексю | Применение амитриптилина для блокирования мозговых гемиканалов и способ потенцирования его влияния in vivo |
AU2016302235A1 (en) | 2015-08-06 | 2018-03-08 | The Feinstein Institutes For Medical Research | Hemichannel extracellular domain-specific agents for treating sepsis |
AU2016309948B2 (en) * | 2015-08-14 | 2021-05-20 | The University Of Sydney | Connexin 45 inhibition for therapy |
CN105566495B (zh) * | 2016-01-27 | 2019-10-22 | 上海科技大学 | 一种特异性抑制连接蛋白26的全人抗体 |
EP3419998A4 (en) * | 2016-02-26 | 2019-09-25 | The Board of Regents of The University of Texas System | CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF |
US11433116B2 (en) * | 2016-04-14 | 2022-09-06 | Cedars-Sinai Medical Center | GJA1 isoforms protect against metabolic stress |
JP2019522041A (ja) * | 2016-05-03 | 2019-08-08 | ユニバーシティ・オブ・オークランド | 新規のペプチド及びペプチド模倣体 |
EP3503908A1 (en) * | 2016-08-23 | 2019-07-03 | The Cleveland Clinic Foundation | Cancer treatment using cx26 blocking peptides |
WO2018061784A1 (ja) | 2016-09-30 | 2018-04-05 | 富士フイルム株式会社 | 水溶液、着色組成物、インクジェット記録用インク、インクジェット記録方法、及びインクカートリッジ |
US11466069B2 (en) | 2017-04-28 | 2022-10-11 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
CA3070089A1 (en) | 2017-07-19 | 2019-01-24 | Auckland Uniservices Limited | Cytokine modulation |
EP3684422B1 (en) * | 2017-09-20 | 2023-12-20 | The Regents of the University of California | Connexin-43 gene therapy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy |
CN107469071B (zh) * | 2017-09-29 | 2021-01-26 | 河南大学 | Connexin模拟肽在制备预防或治疗急性肺损伤药物中的应用 |
CN108066744A (zh) * | 2017-12-29 | 2018-05-25 | 于海龙 | 细胞连接蛋白43模拟肽Gap19在制备治疗脑出血药物中的用途 |
CN108588075A (zh) * | 2018-05-03 | 2018-09-28 | 天德悦(北京)生物科技有限责任公司 | 人Cx43基因干扰序列、shRNA-Cx43病毒及低表达Cx43蛋白的细胞系 |
WO2019222800A1 (en) * | 2018-05-21 | 2019-11-28 | Hudson Institute of Medical Research | Methods for the treatment or prevention of autoimmune or autoinflammatory diseases |
AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
CN111484981B (zh) * | 2020-04-26 | 2021-02-02 | 四川省人民医院 | 一种用于构建视网膜新生血管疾病模型的方法和应用 |
JP7036158B2 (ja) * | 2020-07-08 | 2022-03-15 | 株式会社リコー | 表示画像作成装置および画像表示装置 |
KR20230042744A (ko) | 2020-07-31 | 2023-03-29 | 알라맵 테라퓨틱스, 인크. | 항-코넥신 항체 제제 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4861757A (en) * | 1986-11-14 | 1989-08-29 | Institute Of Molecular Biology | Wound healing and bone regeneration using PDGF and IGF-I |
JPH0539594Y2 (hu) * | 1988-08-05 | 1993-10-07 | ||
US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
GB2273932A (en) | 1992-11-24 | 1994-07-06 | Stiefel Laboratories | Stable oligonucleotides |
GB9425930D0 (en) | 1994-12-22 | 1995-02-22 | Procter & Gamble | Silicone compositions |
US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
CA2273203A1 (en) | 1996-12-02 | 1998-06-11 | Dyad Pharmaceutical Corporation | Antisense inhibition of human adhesion molecules |
US6458590B1 (en) * | 1997-08-07 | 2002-10-01 | The United States Of America, As Represented By The Department Of Health And Human Services | Methods and compositions for treatment of restenosis |
JP4404479B2 (ja) * | 1997-12-09 | 2010-01-27 | チルドレンズ・メディカル・センター・コーポレイション | 血管内皮増殖因子の可溶性インヒビターおよびその使用 |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AU776512B2 (en) * | 1999-01-27 | 2004-09-09 | David Laurence Becker | Formulations comprising antisense nucleotides to connexins |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
WO2001045730A2 (en) * | 1999-12-20 | 2001-06-28 | Immunex Corporation | Tweak receptor |
JP2004531461A (ja) * | 2000-10-18 | 2004-10-14 | チルドレンズ メディカル センター コーポレーション | オステオポンチン被覆表面および使用方法 |
CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
EP1435925A2 (en) * | 2001-10-17 | 2004-07-14 | University of Wales College of Medicine | Gap junctions and edhf |
EP1469875A1 (en) * | 2002-01-29 | 2004-10-27 | Wyeth | Compositions and methods for modulating connexin hemichannels |
JP2003238441A (ja) * | 2002-02-08 | 2003-08-27 | 英行 ▲高▼野 | 血管新生抑制剤 |
WO2003096981A2 (en) * | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
JP2004073182A (ja) * | 2002-05-24 | 2004-03-11 | Takeda Chem Ind Ltd | インスリン抵抗性改善剤 |
AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
WO2004085479A2 (en) * | 2003-03-26 | 2004-10-07 | Apogenix Gmbh | Treatment of viral infections |
EP1514929A1 (en) | 2003-09-12 | 2005-03-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
SG187381A1 (en) * | 2003-12-03 | 2013-02-28 | Coda Therapeutics Nz Ltd | Antisense compounds targeted to connexins and methods of use thereof |
DE102004027422A1 (de) | 2004-06-04 | 2005-12-29 | Boehringer Ingelheim Microparts Gmbh | Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen |
AU2005319155B2 (en) | 2004-12-21 | 2013-01-31 | Musc Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
WO2006134494A2 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and therapeutic uses thereof |
AU2006326791A1 (en) * | 2005-12-16 | 2007-06-21 | Arla Foods Amba | Bovine osteopontin formulations for the improvement of the wound healing process |
KR20100027091A (ko) | 2006-11-15 | 2010-03-10 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
ES2527131T3 (es) | 2006-12-11 | 2015-01-20 | Coda Therapeutics, Inc. | Polinucleótidos anticonexina como composiciones para la curación alterada de heridas |
US8323968B2 (en) * | 2007-03-02 | 2012-12-04 | National University Of Ireland, Galway | Osteopontin for the prediction and treatment of cardiovascular diseases |
ES2660906T3 (es) | 2007-05-31 | 2018-03-26 | Anterios, Inc. | Nanopartículas de ácido nucleico y usos de las mismas |
CN101970663A (zh) | 2007-12-11 | 2011-02-09 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
CN102105492A (zh) | 2007-12-11 | 2011-06-22 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
JP2011507860A (ja) | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用 |
JP2011507855A (ja) | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 外科的癒着の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた抗コネキシンペプチドの使用 |
CA2710227A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of surgical adhesions |
US8975237B2 (en) | 2007-12-21 | 2015-03-10 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
CA2710386A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Improved medical devices |
WO2009085269A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions |
CA2710382A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of orthopedic conditions |
EP2252690A2 (en) | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
WO2009085275A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
EP2240583A2 (en) | 2008-01-07 | 2010-10-20 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
EP2307546A1 (en) | 2008-06-04 | 2011-04-13 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
-
2006
- 2006-02-03 WO PCT/IB2006/001961 patent/WO2006134494A2/en active Application Filing
- 2006-02-03 DK DK06795121.0T patent/DK1959981T3/da active
- 2006-02-03 EP EP06795121.0A patent/EP1959981B1/en active Active
- 2006-02-03 KR KR1020167013933A patent/KR101840445B1/ko active IP Right Grant
- 2006-02-03 CN CN201711202710.2A patent/CN108324923A/zh active Pending
- 2006-02-03 AU AU2006257283A patent/AU2006257283A1/en not_active Abandoned
- 2006-02-03 ES ES06795121T patent/ES2766549T3/es active Active
- 2006-02-03 EP EP12172476A patent/EP2510937A1/en not_active Withdrawn
- 2006-02-03 CA CA002596412A patent/CA2596412A1/en not_active Abandoned
- 2006-02-03 EP EP12172478A patent/EP2510939A1/en not_active Withdrawn
- 2006-02-03 US US11/883,739 patent/US9248141B2/en not_active Expired - Fee Related
- 2006-02-03 KR KR1020077020138A patent/KR20080031154A/ko active Search and Examination
- 2006-02-03 KR KR1020187007409A patent/KR102073629B1/ko active IP Right Grant
- 2006-02-03 EP EP12172477A patent/EP2510938A1/en not_active Withdrawn
- 2006-02-03 EP EP12172475.1A patent/EP2662088A3/en not_active Withdrawn
- 2006-02-03 JP JP2007553747A patent/JP5964538B2/ja not_active Expired - Fee Related
- 2006-02-03 KR KR1020147033485A patent/KR20150004906A/ko not_active Application Discontinuation
- 2006-02-03 HU HUE06795121A patent/HUE047335T2/hu unknown
- 2006-02-03 CN CN200680010590.XA patent/CN101573131B/zh not_active Expired - Fee Related
-
2011
- 2011-03-02 AU AU2011200924A patent/AU2011200924A1/en not_active Abandoned
-
2012
- 2012-03-02 JP JP2012047133A patent/JP2012107065A/ja not_active Withdrawn
-
2014
- 2014-06-12 JP JP2014121150A patent/JP2014169325A/ja not_active Withdrawn
-
2016
- 2016-02-01 US US15/012,732 patent/US10201590B2/en not_active Expired - Fee Related
- 2016-08-15 JP JP2016159323A patent/JP2016193942A/ja not_active Withdrawn
-
2018
- 2018-04-13 JP JP2018077563A patent/JP2018111724A/ja active Pending
-
2019
- 2019-01-25 HK HK19101379.8A patent/HK1258903A1/zh unknown
- 2019-08-15 JP JP2019149110A patent/JP2019194268A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE047335T2 (hu) | Anti-connexin 43 vegyületek, krónikus sebek kezelésére | |
IL190991A0 (en) | Agents for treating cardiopathy | |
IL185215A0 (en) | 2-cyanobenzenesulfonamide compounds for seed treatment | |
GB0518390D0 (en) | Therapeutic compounds | |
AP2007004128A0 (en) | Tricyclic-nucleoside compounds for treating viral infections | |
HU0500170D0 (en) | New compounds with therapeutic effects | |
GB0518237D0 (en) | Therapeutic compounds | |
GB0509326D0 (en) | Therapeutic compounds | |
GB0509573D0 (en) | Therapeutic compounds | |
IL190727A (en) | Compounds for use in the treatment or prevention of hematologic malignant tumors | |
GB0518361D0 (en) | Therapeutic compounds | |
PT1940916T (pt) | Composto macromolecular tendo estequiometria controlada | |
GB0522881D0 (en) | Therapeutic compounds | |
GB0509405D0 (en) | Therapeutic compounds | |
EP1933858A4 (en) | MEDICAL COMPOSITION FOR TREATING INJURIES | |
GB0524103D0 (en) | Healing | |
GB0513747D0 (en) | Therapeutic compounds | |
EP1883405A4 (en) | METHODS OF TREATING NEPHROLITHIASIS | |
GB0522130D0 (en) | Therapeutic compounds | |
GB0516068D0 (en) | Well treatment | |
EP1958952A4 (en) | IONIC CONNECTIONS | |
GB0526107D0 (en) | Therapeutic Compounds | |
MY143527A (en) | Wood treatment | |
GB0525540D0 (en) | New treatment | |
GB0518235D0 (en) | Therapeutic compounds |